Ecnoglutide shows no clinically significant pharmacokinetic interactions with rosuvastatin or digoxin
Background
As novel GLP-1 receptor agonists like ecnoglutide gain traction for Type 2 diabetes and obesity management, understanding their drug-drug interaction profile is crucial. Patients often have comorbidities like dyslipidemia and cardiac conditions, necessitating co-administration of medications such as rosuvastatin (a statin for cholesterol) and digoxin (a cardiac glycoside for heart failure). Ensuring these vital drugs maintain their efficacy and safety when combined with GLP-1 agonists is a critical step in clinical development.
Study Design
This open-label, single-sequence crossover Phase 1 study enrolled 28 healthy volunteers. Participants received single doses of rosuvastatin (10 mg) and digoxin (0.25 mg) in two periods: once alone, and once during steady-state subcutaneous ecnoglutide (1.2 mg) treatment. The primary endpoint was the assessment of pharmacokinetic (PK) parameters for both rosuvastatin and digoxin, including area under the concentration-time curve (AUC) and maximum plasma concentration (Cmax), to determine any co-administration effects.
Results
Co-administration of ecnoglutide did not affect rosuvastatin or digoxin to a clinically relevant degree. For rosuvastatin, the geometric mean (GM) ratio [90% confidence interval (CI)] of the area under the concentration-time curve from time zero to infinity (AUCinf) (with ecnoglutide vs. alone) was 106% (94%, 120%). For digoxin, the GM ratio for AUCinf was 84% (76%, 94%). Both values fell within the standard bioequivalence range, indicating no significant interaction. The maximum plasma concentration (Cmax) of digoxin decreased slightly from 1.39 to 1.31 ng/mL but remained within the therapeutic window. The most common adverse events (AEs) were weight loss and gastrointestinal AEs, consistent with the known pharmacology of glucagon-like peptide-1 (GLP-1) receptor agonists. No serious AEs were reported. > Notably, ecnoglutide treatment led to a substantial body weight reduction, with a mean decrease of 11.2% across the 14-week intervention period.
Key Findings
- Ecnoglutide co-administration did not clinically affect rosuvastatin PK, with AUC GM ratio of 106% (94%, 120%).
- Ecnoglutide co-administration did not clinically affect digoxin PK, with AUC GM ratio of 84% (76%, 94%).
- Digoxin Cmax decreased slightly from 1.39 to 1.31 ng/mL but remained therapeutic.
- No dose adjustments for rosuvastatin or digoxin are required when co-administered with ecnoglutide.
- Ecnoglutide treatment led to a mean body weight reduction of 11.2% over 14 weeks.
Why It Matters
This study provides important safety and pharmacokinetic data, indicating that ecnoglutide can be co-administered with rosuvastatin and digoxin without requiring routine dose adjustments for these medications. This simplifies treatment regimens for patients managing Type 2 diabetes or obesity alongside dyslipidemia or cardiac conditions. While no dose adjustments are generally needed, close clinical and plasma monitoring is still advised during digoxin co-administration, particularly in patients with renal impairment, due to its narrow therapeutic index. This finding supports the broader clinical utility of ecnoglutide by reducing potential drug-drug interaction concerns.
ecnoglutide
glp-1-agonist
pharmacokinetics
drug-interaction
rosuvastatin
digoxin